Aslam Anis, University of British Columbia
Population and Public Health
Professor
Vancouver, British Columbia
aslam.anis@ubc.ca
Office:
(604) 806-8712
Expert In
Bio/Research
Dr. Aslam Anis is a health economist and Professor in the School of Population and Public Health (SPPH) at the University of British Columbia (UBC). Since 2006, Dr. Anis has been the Director of the Centre for Health Evaluation and Outcomes Sciences (CHЙOS), a renowned multidisciplinary health ou...
Click to Expand >>
Click to Expand >>
Bio/Research
Dr. Aslam Anis is a health economist and Professor in the School of Population and Public Health (SPPH) at the University of British Columbia (UBC). Since 2006, Dr. Anis has been the Director of the Centre for Health Evaluation and Outcomes Sciences (CHЙOS), a renowned multidisciplinary health outcomes research unit within Providence Health Care Research Institute in Vancouver, Canada. He is also the National Co-Director of the CIHR Canadian HIV Trials Network (CTN) and Senior Scientist, Arthritis Research Centre of Canada (ARC). Dr. Anis currently oversees economic analysis and health services research activities across Providence Health Care, with scholars who trained under Dr. Anis operating across CHЙOS, CTN, the Heart and Lung Institute (HLI), and the Collaboration for Outcomes Research and Evaluation (CORE) in UBC’s Faculty of Pharmaceutical Sciences. At UBC, Dr. Anis is the theme co-lead for Health Services and Systems and Director of SPPH’s Health Administration Program, which in 2002 he transformed to an executive-style degree program offered in collaboration with UBC’s Sauder School of Business.
Dr. Anis’s research activities are extensive and his work has been instrumental in shaping economic policies in Canada, notably those governing access to anti-retroviral therapy (ART) for persons living with HIV/AIDS. Dr. Anis was among the first scholars worldwide to demonstrate the cost-effectiveness of ART and he has published widely in the peer-reviewed literature on health resource use and costs among HIV/AIDS patients treated and not treated with ART. As the National Co-Director of the CTN, Dr. Anis is a co-investigator on a number of large multi-centered clinical trials that are facilitating prospective economic evaluations of interventions in HIV/AIDS. In the areas of HIV clinical trials and related policies, Dr. Anis is a methodological leader and a recognized expert. Research by Dr. Anis in the area of pharmaceutical pricing policies in Canada has also attracted worldwide attention since the 1990s and he continues to publish on the economic impact of changing drug price regulations. Dr. Anis’s expertise in health economics as pertaining to the pharmaceutical industry encompasses the relationship between government regulations and corporate behaviour, competition policy, patent infringement and international trade in pharmaceuticals. Dr. Anis has extensive experience conducting cost-effectiveness studies of new drugs especially biologic therapies for the treatment of inflammatory arthritis and he regularly consults with industry and governments in the context of formulary approval decisions.
From 2006 to 2009, Dr. Anis served as a member of the Canadian Institute for Health Research (CIHR) HIV/AIDS Research Advisory Committee, whose mandate is to make recommendations to the Institute of Infection and Immunity regarding research priorities for HIV/AIDS. Dr. Anis also served on the Public Health Agency of Canada and CIHR Special Planning Committee to review the Federal Initiative on HIV/AIDS in Canada from 2006 to 2007. Provincially, Dr. Anis has served in various capacities at the Michael Smith Foundation for Health Research (MSFHR) including its Research Advisory Council. Dr. Anis consults widely with federal, provincial, and private agencies, including Health Canada, the BC Ministry of Health, Industry Canada, the Canadian Medical Association, and Canadian and international pharmaceutical manufacturers. He actively participates in several knowledge transfer activities, including participation on government panels and involvement with consumer associations. Dr. Anis has published more than 150 peer-reviewed papers and garnered in excess of $125 million in peer-reviewed research funding. For his significant contributions in health economics, Dr. Anis was recently inducted as a Fellow of the Canadian Academy of Health Sciences.
Click to Shrink <<
Dr. Anis’s research activities are extensive and his work has been instrumental in shaping economic policies in Canada, notably those governing access to anti-retroviral therapy (ART) for persons living with HIV/AIDS. Dr. Anis was among the first scholars worldwide to demonstrate the cost-effectiveness of ART and he has published widely in the peer-reviewed literature on health resource use and costs among HIV/AIDS patients treated and not treated with ART. As the National Co-Director of the CTN, Dr. Anis is a co-investigator on a number of large multi-centered clinical trials that are facilitating prospective economic evaluations of interventions in HIV/AIDS. In the areas of HIV clinical trials and related policies, Dr. Anis is a methodological leader and a recognized expert. Research by Dr. Anis in the area of pharmaceutical pricing policies in Canada has also attracted worldwide attention since the 1990s and he continues to publish on the economic impact of changing drug price regulations. Dr. Anis’s expertise in health economics as pertaining to the pharmaceutical industry encompasses the relationship between government regulations and corporate behaviour, competition policy, patent infringement and international trade in pharmaceuticals. Dr. Anis has extensive experience conducting cost-effectiveness studies of new drugs especially biologic therapies for the treatment of inflammatory arthritis and he regularly consults with industry and governments in the context of formulary approval decisions.
From 2006 to 2009, Dr. Anis served as a member of the Canadian Institute for Health Research (CIHR) HIV/AIDS Research Advisory Committee, whose mandate is to make recommendations to the Institute of Infection and Immunity regarding research priorities for HIV/AIDS. Dr. Anis also served on the Public Health Agency of Canada and CIHR Special Planning Committee to review the Federal Initiative on HIV/AIDS in Canada from 2006 to 2007. Provincially, Dr. Anis has served in various capacities at the Michael Smith Foundation for Health Research (MSFHR) including its Research Advisory Council. Dr. Anis consults widely with federal, provincial, and private agencies, including Health Canada, the BC Ministry of Health, Industry Canada, the Canadian Medical Association, and Canadian and international pharmaceutical manufacturers. He actively participates in several knowledge transfer activities, including participation on government panels and involvement with consumer associations. Dr. Anis has published more than 150 peer-reviewed papers and garnered in excess of $125 million in peer-reviewed research funding. For his significant contributions in health economics, Dr. Anis was recently inducted as a Fellow of the Canadian Academy of Health Sciences.
Click to Shrink <<